Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase - sprookjes - yvandenbroek - TriplyDB

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

http://www.wikidata.org/entity/Q27488428

about

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus.Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders Antiviral drugs against hepatitis C virus.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor HCV drug discovery aimed at viral eradication.Emerging therapies for hepatitis C virus.Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.Antiviral therapy for hepatitis C virus: beyond the standard of care.Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor Discontinued drugs in 2012 - 2013: hepatitis C virus infection.Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.

P2860

Q26783056-67B7AEE4-B2B1-4FDF-AA00-6D7E59A2324B Q27490956-21A11405-85AC-4F39-89C4-4021D0675486 Q27679235-BD2DFDFB-CCBD-40E4-82CC-9D0476877103 Q32183060-FCC63490-3257-4B3C-8847-1984AC11D8F9 Q33852451-1CE2B5D3-FB23-422E-B262-4E9EDB218149 Q34399501-27EA8A6C-CF23-4C09-BDC4-F8D9C2DDAC9C Q34561257-7BE70DD3-93A7-469C-A719-0339F80D4467 Q34596328-A846830A-565C-4FE2-8ECD-417B3C76498A Q34597666-1DE95BD7-D7A6-4D50-A532-DD255E786A6B Q35105567-036DA809-88C4-4B86-B7C7-9C75D9681584 Q35653358-078E2312-F554-474F-8BEE-E697034F6B16 Q35806182-1E446BEE-02FD-4C0F-930B-B0964264B9AF Q37263558-09592CD4-57A2-4323-BA61-FB6094944432 Q37664059-3612FC1E-77E5-4E57-80DB-A8AB5605A7AB Q37772514-47A9CF7E-A19A-4D2F-8E87-8F045A7365CE Q37855859-369AD462-6F81-463A-A770-5DFC58E7C0C0 Q37945201-93D08485-FD8B-4AB6-99E9-8C7B4922331A Q38283097-E9F6A508-5720-46E4-8C62-49502E45EAEB Q38427538-B1AD1D26-59D3-4928-B65F-85BBA972AF00 Q39100351-0BB2927C-F9F8-4492-B775-4510BC73E15A Q39432758-0DD338EA-8D22-4018-988F-F2AB72A2E70C Q39627463-D1C50B74-3310-4915-8019-D4CD0949F499 Q40040199-C6D7BCE7-796B-4450-BC51-05DCB864929B Q41683654-2DF19551-124C-4E3A-BF4A-9FC01CCA1228 Q42286521-18C358B7-6145-4873-828C-E6D3D3CC587A Q43036045-E952F3D0-E3C5-4D3C-8E85-5A9C1CB94D3A

P2860

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

http://www.wikidata.org/entity/Q27488428

description

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

article scientifique (publié 2009-06)

@fr

articolo scientifico (pubblicato il 2009-06)

@it

artigo científico (publicado na 2009-06)

@pt

artículu científicu espublizáu en 2009

@ast

im Juni 2009 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: June 2009)

@en

vedecký článok (publikovaný 2009-06)

@sk

vetenskaplig artikel (publicerad på 2009-06)

@sv

name

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@ast

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@en

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@nl

type

label

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@ast

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@en

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@nl

prefLabel

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@ast

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@en

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@nl

P1433

Q27488428-4891BE24-FCD5-49C6-8884-14B88B4F0678

P1476

Q27488428-06346910-09AE-484C-BB65-FCEE6A3461E2

P2093

Q27488428-12F1AF5F-DFEA-4D8D-AE34-523A0DD4E03F

Q27488428-2F1B9758-6AA8-4320-AC47-6568239EF8D3

Q27488428-4D278037-2FB9-46E2-BCC5-84D9D395107E

Q27488428-6765B659-1576-4D72-9BB0-6C8948FC89B6

Q27488428-6CF7BCA9-1223-40E4-8772-56A507E452CF

Q27488428-81DCCA13-4678-4E2E-A596-9413DB1C7C26

Q27488428-8B98BC41-7189-484D-AF60-4D2451A9C47D

Q27488428-9DA61D10-BC33-4B34-B562-D836422238AA

Q27488428-A1D5A7B8-1A56-4C2D-B2A5-C4FC509F5B61

Q27488428-BB1CF59C-407A-4754-895B-9AAE33CEF314

P2860

Q27488428-063FEB6F-2425-4AD2-A7A2-F47E9060CA77

Q27488428-105C41EB-8B93-47C8-8E3C-9F136E2193BB

Q27488428-11959023-202D-426A-8934-491914920D0D

Q27488428-178C8BE5-C577-40C7-85CE-9D6D644B36C9

Q27488428-181F392A-9478-4C47-8CF0-9460610AE367

Q27488428-1E106132-6D2B-4E45-B5BE-B604797FAC7F

Q27488428-1F611B29-3BDB-4E80-B704-BCF49D6B6D84

Q27488428-261DC6AF-93AD-4299-ACFC-168B6F205E6A

Q27488428-331ECD24-9617-4B61-BFBE-A3BA7F50EB8D

Q27488428-33AAA5AD-3B44-4F15-A10A-5B8A7724ED54

P304

Q27488428-3F37FA4A-986B-42A5-AD04-46A910B8655E

P31

Q27488428-9BDCFCAE-319F-4A88-87E4-0DD077513A34

P356

Q27488428-F14F1141-2EA9-41AC-B303-1B6750C9643D

P407

Q27488428-417196E6-B390-40F1-B098-5EA722513902

P433

Q27488428-E83F85BB-E48D-49F5-97AA-6A84D37BF697

P478

Q27488428-2788133F-A95D-4F3A-9600-503ECBFC58C7

P577

Q27488428-3B28993D-FB89-4D01-A1E6-5352F8988D1F

P698

Q27488428-66E0A786-F889-4022-997D-0FB35C0783E4

P932

Q27488428-7E09F80A-C18B-483B-89BB-BF6C0159F64F

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Preclinical Characterization o ...... s RNA-Dependent RNA Polymerase

@en

P2093

Amy K Patick

http://www.w3.org/2001/XMLSchema#string

Angelica Linton

http://www.w3.org/2001/XMLSchema#string

Cristina Lewis

http://www.w3.org/2001/XMLSchema#string

Heather Skor

http://www.w3.org/2001/XMLSchema#string

Hui Li

http://www.w3.org/2001/XMLSchema#string

Javier Gonzalez

http://www.w3.org/2001/XMLSchema#string

Jim Nonomiya

http://www.w3.org/2001/XMLSchema#string

Joanne P Graham

http://www.w3.org/2001/XMLSchema#string

John Tatlock

http://www.w3.org/2001/XMLSchema#string

Koleen J Herlihy

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical significance of hepatitis C virus genotypes

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase Inhibitor

Development of a Novel Dicistronic Reporter-Selectable Hepatitis C Virus Replicon Suitable for High-Throughput Inhibitor Screening

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus

P304

2544-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01599-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19307358

http://www.w3.org/2001/XMLSchema#string

P932

2687230

http://www.w3.org/2001/XMLSchema#string